Ensysce Q1 net loss narrows to $1.9M; PF614-MPAR trial Part 1 completes, patent allowed for OUD candidate

Ensysce Biosciences, Inc.

2025-Q1 EPS reported -$1.39 revenue$1,319,772

Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.
Cash $3.1M at March 31, 2025; subsequent warrant exercises raised $2.2M gross.
PF614-MPAR-102 Part 1 confirmed overdose protection at higher doses; Parts 2 & 3 enrollment underway.
U.S. patent allowed for PF9001 (OUD) covering composition of matter and method of use.
Federal grant funding increased to $1.3M from $0.3M, supporting MPAR and OUD programs.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001641172-25-009949
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2025-05-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.455054+00:00
generated_at: 2026-05-21T16:37:06.744010+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001641172-25-009949
json_url: https://secwatch.observer/filing/0001641172-25-009949.json
markdown_url: https://secwatch.observer/filing/0001641172-25-009949.md
text_url: https://secwatch.observer/filing/0001641172-25-009949.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/0001641172-25-009949-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001641172-25-009949

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.